UTv Videos

"When we think about what burnout does to our workforce, the ramifications are significant," says Andrew M. Harris, MD.

"The future's bright, and I think we have a lot more people engaged," says Denise Asafu- Adjei, MD, MPH.

"There's a potential for a more nuanced approach to screening where you assess baseline at 40 for all races, so that you can then determine who needs to be screened regularly or not," says Adam Murphy, MD, MBA, MSCI.

“Whenever you're talking about the risk of incontinence, you should know your own data and not cite a specialist who has done a [large amount] of cases,” says Ricardo M. de Oliveira Soares, MD.

"Helping urologists establish practices in rural areas and incentivizing those practices is so important," says Kevin Koo, MD, MPH.

“There's a lot of talk about Roe v. Wade affecting the reproductive health of women. This implies that it's also affecting reproductive health decisions for men,” says Sarah Vij, MD.

“When I'm discussing surgery, or any kind of treatment for prostate cancer, with patients, I always talk about the ‘trifecta,’ “ says Ricardo M. de Oliveira Soares, MD.

“Major bladder reconstructive surgeries have the most room for improvement, particularly surgeries involving a bowel anastomosis,” says Sarah Hecht, MD.

“I just hope that people are as enthusiastic about this new company, as [I] and my coauthors are,” says Ruchika Talwar, MD.

“What we found is that the majority of these companies…offered our ‘secret shopper’ testosterone therapy,” says Joshua A. Halpern, MD, MS.

“The biggest question that arose from this is, ‘Why is there such a lack of large familial genetic disorder epidemiological studies?’ says Laura Bukavina, MD, MPH.

“We need to continue to push the field forward, and the way we do that is to evaluate the risk factors and to stratify patients based on their risk factors and their genetic components,” says Laura Bukavina, MD, MPH.

Dr. Andre Goy gives insight into the center’s personalized experience discussing his approach to a patient’s treatment journey. Watch now.

Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.

“The association between CKD and end-stage renal failure and increasing risk of kidney cancer is a really striking and important association to be aware of,” says Sarah P. Psutka, MD, MS.

“You can't just have all or none treatments. You've got to have a middle ground for people who are going to look for that,” says John R. Valvo, MD.

“With this study, we gained a better understanding of the features of third line therapy for overactive bladder, that patients find favorable and unfavorable,” says Anjali Kapur, MD.

“The short-term goals are really community building [and] relationship building,” says Randy Vince Jr, MD.

“I think anecdotally speaking there have been a lot of practices and states corroborating our results,” says Rutul Patel, DO, MS.

Treatment of azoospermia after exogenous testosterone use may require aggressive medical therapy, according to Kelli Gross, MD.

Physician Coach Support is a free resource that provides confidential, one-on-one peer support for clinicians.

Study authors found a rise in public interest in vasectomies, “particularly in states where abortion is or is expected to be prohibited.”

“One of the first pieces of advice I would give is to make sure you have the OR space available for the equipment,” says Jennifer A. Linehan, MD.

“We did not happen to find that vitamin D compared to placebo lowered the odds of having incontinence at year 2 or year 5. Nor did it lower the odds of having overactive bladder symptoms at year 5,” says Alayne Markland, DO.

“We really need to be thoughtful about how our treatment recommendations may induce financial toxicity in patients with advanced prostate cancer,” says Daniel D. Joyce, MD.

“I feel like [HIFU] provided patients this intermediary treatment option…It was less invasive than radiation and surgery, but still provided cancer control, or at least for some patients delayed the time until they needed a more radical treatment,” says Jennifer A. Linehan, MD.

“We found that treatment-related out-of-pocket costs were 18 times higher for those patients treated with novel hormonal therapies compared to those who were just on standard ADT,” says Daniel D. Joyce, MD.

“I think what becomes important with this is how we need to do our part in terms of not only engaging our non-urology colleagues to help in educating them about these most common problems in urologic conditions, but also really become [advocates] at the medical school level,” says Jessica Kreshover, MD.